Objective: To evaluate whether intravenous immunoglobulin reduces mortality and length of hospital stay in the treatment of neonatal sepsis.
Introduction
Neonatal infections show peculiar characteristics that are not observed in any other period of life. 1,2 Newborns, especially premature infants, have a fragile physical barrier and an immature immune function, what make them susceptible to invading bacteria (which normally would be only colonizing bacteria). 1, 2 Sepsis is one of the most common conditions in the neonatal period. 3 It is a clinical syndrome characterized by a systemic inflammatory response in the presence -or as the result -of a suspected or confirmed infection. 4 Infant mortality remains high in Brazil, with a rate of 17.6 in 2008, according to data provided by the IT Department of the Brazilian Unified Health System (DATASUS). Most of these deaths occur in the neonatal period, with a rate of 10.3 in 2008. Sepsis is an important cause of mortality in this period. Despite the advances in the treatment and intensive care, the global incidence of neonatal sepsis remains high, from one to eight cases/1,000 live births, associated with a case-fatality ranging from 10 to 50%. 5 Intravenous immunoglobulin (IVIg) has been considered as an adjuvant in the treatment of neonatal sepsis. [6] [7] [8] Knowing the characteristics of the fetal immune system development and the defense mechanism failures to protect infants against neonatal pathogens has provided theoretical support for the use of IVIg. 9, 10 IVIg is used to provide specific antibodies of the IgG class to be connected to cell-surface receptors, promoting opsonization, antibodydependent cytotoxic activity, and complement activation, while increasing neutrophil chemotaxis. 8 Although it has been demonstrated that the use of IVIg is safe, its effectiveness remains questionable. 11 Thus, the objective of the present systematic review is to investigate whether the adjuvant use of IVIg reduces mortality and length of hospital stay in the treatment of neonatal sepsis.
Methods
The MEDLINE database was searched using the pubmed. AND infant, newborn. To refine the search, we used the Therapy/Narrow methodological filter.
The title and abstract of each article were analyzed, and the eligible articles were selected for full text reading.
The inclusion criteria were: to be a randomized clinical trial; to compare the use of IVIg with the use of standard antibiotic therapy; to be written in Portuguese, English or Spanish; and to be conducted in patients aged less than 28 days. The exclusion criteria were: follow-up losses higher than 20%; use of IVIg in the prophylaxis of patients with increased risk for sepsis; and inclusion of patients older than 28 days.
The full text of the selected studies was read and critically analyzed. Only those studies with a score higher than or equal to 3 on the instrument designed by Jadad et al. 12 were included in the final selection and data analysis.
We analyzed the following outcomes: mortality and length of hospital stay. Dichotomous variables were analyzed based on the difference in the absolute risk (AR), with its 95% confidence interval (95%CI) and the number needed to treat (NNT) or number needed to harm (NNH) using the CATmaker software. Continuous variables were analyzed using the difference between the means, with its 95%CI.
We used the Review Manager 5.1.1 software to perform the meta-analysis.
Results
The review of the literature was completed in February 2012. We found 53 studies, of which nine [13] [14] [15] [16] [17] [18] [19] [20] [21] were selected for full text reading. Two other studies were selected for full text reading by means of manual search. 22, 23 Of the 11 selected studies, four articles were not included in the data analysis: the full text of one of the studies 18 was not available at the Regional Library of Medicine (BIREME) and three articles were excluded. [19] [20] [21] The reasons for exclusion were: low methodological quality (Jadad et The main characteristics of the seven studies included are described in Tables 1 and 2 .
Mortality
All studies provided data on mortality; 3,756 patients were analyzed regarding this outcome.
Only the study by Haque et al. 23 
Study Population Sample Jadad
Brocklehurst et al. 13 Confirmed or clinical sepsis with weight < 1,500 g or positive culture or need for ventilatory support 3,493 5
Ahmed et al. 22 Clinical sepsis, GA < 33 weeks 60 3
Shenoi et al. 14 Early clinical sepsis 58 3
Mancilla-R et al. 16 Confirmed sepsis 37 4
Weisman et al. 15 Early confirmed sepsis, weight between 500 and 2,000 g, GA < 34 weeks 31 3
Christensen et al. 17 Early clinical sepsis 24 3
Haque et al. 23 Clinical sepsis, GA 28-37 weeks 60 4
The heterogeneity test (I 2 ) demonstrated homogeneity among the studies, except for the study by Haque et al., 23 because this was the only study showing a statistically 
Mean length of hospital stay
Only five studies [13] [14] [15] [16] 22 provided information on the mean length of hospital stay. Regarding this outcome, we analyzed 3,672 patients.
Only two studies showed statistically significant difference between the means of length of hospital stay of two groups. In the study by Mancilla-R et al., 16 
Discussion
The present review of the literature showed no significant differences in the primary outcome (mortality) and demonstrated a significant reduction of 1.24 days in the mean length of hospital stay in the IVIg group. Regarding the primary outcome, only the study by Haque et al. 23 was heterogeneous in relation to the others, and in the secondary outcome, only the study by Mancilla-R et al. 16 was heterogeneous compared with the others.
The I 2 shows and quantifies how heterogeneous the effects found in the studies are. The studies placed inside the funnel plot are homogeneous, whereas the studies outside the funnel plot are heterogeneous; therefore they cannot be compared and were excluded from the overall analysis.
When there is high heterogeneity between the effects of the studies, the next step is to perform a sensitivity analysis, what can be done using diverse methods. Based on this scenario, we chose to revise the meta-analysis, excluding the heterogeneous studies.
The present review of the literature included seven articles. [13] [14] [15] [16] [17] 22, 23 The most recent article, Brocklehurst et al., 13 is a multicenter study involving nine countries. Of the studies included, this was the most important one. It included a population of 3,493 patients, a sample much larger than that of the other studies, whose samples ranged from 24 to 60 patients. This was the only study with a score of 5 according to the instrument designed by Jadad et al. 12 The study by Ahmed et al. 22 was conducted in Bangladesh and it was not found in the search of the main articles, being retrieved by means of manual search. The authors knew this study because it was included in the last systematic review 11 published on the same topic. This study did not describe the therapy used in the control group and it had Use of intravenous immunoglobulin in neonatal sepsis -Franco AC et al. The study by Mancilla-R et al. 16 was conducted in
Mexico. It was a randomized trial, but the authors did not describe the method used for randomization. It had a score of 4 on the scale by Jadad et al. 12 This was the only heterogeneous study in comparison with the others regarding to the outcome mean length of hospital stay and, therefore, it was excluded from our overall analysis.
The study by Weizman et al. 15 was a multicenter study involving two research arms: the use of IVIg to prevent neonatal sepsis and the use of IVIg in the treatment of neonatal sepsis. The results on prevention were ignored in the present review. Its sample included only 31 patients, and albumin solution placed in bottles identical to the ones used for the study drug was used as placebo.
Christensen et al. 17 conducted a multicenter study without blinding, and its score according to Jadad et al. 12 was 3. This is the study with the smallest sample (24 patients).
The study by Haque et al. 23 was conducted in Saudi Arabia. It was not found in the search of the main articles as well, being retrieved by means of manual search. It had a score of 4 according to Jadad et al. 12 because the authors did not describe the randomization method. This study was heterogeneous in relation to the others in terms of the outcome mortality; thus, it was excluded from our overall analysis.
Of the studies included in our review, only those by Brocklehurst et al., 13 Shenoi et al., 14 and Weisman et al. 15 calculated the size of the sample in study design.
In relation to the population of these studies, the studies by Mancilla-R et al. 16 and Weizman et al. 15 included only patients with sepsis confirmed by culture; three studies 14, 15, 17 included only early sepsis; and the studies by Weizman et al. 15 and Ahmed et al. 22 included only premature infants (Table 1) .
The therapy regimens of IVIg were different among the studies, as well as the regimen applied to the control groups. Only the studies by Mancilla-R et al., 16 Christensen et al., 17 and Haque et al. 23 mentioned the adjuvant therapy regimens ( Table 2 ). Our review demonstrated that the primary outcome (reduced mortality rate) showed no differences between the intervention and control groups. Furthermore, it demonstrated that although there is a statistically significant reduction in the length of hospital stay in the IVIg group, such difference is clinically irrelevant and its high cost does not warrant its routine use in medical practice.
Conclusion
The present systematic review shows that there is no significant difference in the mortality rate with the adjuvant use of IVIg in the treatment of neonatal sepsis.
Despite the statistically lower result in the IVIg group, the length of hospital stay showed clinically insignificant benefits.
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